Oncotype DX Breast Recurrence Score Hits 2 Million Patients

Event summary

  • Exact Sciences' Oncotype DX Breast Recurrence Score test has been used by over 2 million patients worldwide.
  • The test has helped avoid chemotherapy for an estimated 1.6 million patients.
  • The test is the only genomic assay proven to predict adjuvant chemotherapy benefit.
  • It has earned a Category 1A recommendation in the NCCN Clinical Practice Guidelines.
  • The test is supported by clinical evidence from landmark trials including NSABP B-20, SWOG 8814, TAILORx, and RxPONDER.

The big picture

Exact Sciences' milestone underscores the growing adoption of precision oncology tools in breast cancer treatment. The test's ability to predict chemotherapy benefit and reduce unnecessary treatments aligns with broader trends toward personalized medicine and cost-efficient healthcare. Its global reach and strong clinical validation position it as a key player in the diagnostic testing market.

What we're watching

Market Penetration
Whether Exact Sciences can sustain the growth trajectory of the Oncotype DX test in diverse global markets.
Regulatory Dynamics
How changes in healthcare guidelines may impact the adoption and reimbursement of the test.
Competitive Positioning
The pace at which competitors develop similar predictive and prognostic genomic tests.

Related topics

Biotechnology